Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Akebia Therapeutics received€0.1 Mil more from issuing new shares than it paid to buy back shares.
It received€0.0 Mil from issuing more debt.
It paid€0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.0 Mil from paying cash dividends to shareholders.
It spent€0.9 Mil on other financial activities.
In all, Akebia Therapeuticsspent€0.8 Mil on financial activities for the
three
months ended in Mar. 2026.
Akebia Therapeutics (STU:AX9) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Akebia Therapeutics's issuance of stock for the
three
months ended in Mar. 2026 was €0.1 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Akebia Therapeutics's repurchase of stock for the
three
months ended in Mar. 2026 was €0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Akebia Therapeutics's net issuance of debt for the
three
months ended in Mar. 2026 was €0.0 Mil.
Akebia Therapeutics received€0.0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Akebia Therapeutics's net issuance of preferred for the
three
months ended in Mar. 2026 was €0.0 Mil.
Akebia Therapeutics paid€0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Akebia Therapeutics's cash flow for dividends for the
three
months ended in Mar. 2026 was €0.0 Mil.
Akebia Therapeutics received€0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Akebia Therapeutics's other financing for the
three
months ended in Mar. 2026 was €-0.9 Mil.
Akebia Therapeutics spent€0.9 Mil on other financial activities.
Akebia Therapeutics Cash Flow from Financing Related Terms
Akebia Therapeutics Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Cash Flow from Financing Chart
Akebia Therapeutics Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Akebia Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €-2.5 Mil mean?
Akebia Therapeutics (STU:AX9) has a Cash Flow from Financing of €-2.5 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Cash Flow from Financing too high?
Akebia Therapeutics' current Cash Flow from Financing is €-2.5 Mil. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cash Flow from Financing compare to TKNO and ORGO?
Akebia Therapeutics' Cash Flow from Financing of €-2.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Akebia Therapeutics and its competitors. Akebia Therapeutics's current Cash Flow from Financing is €-2.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.17 — trading 4.3% above its estimated fair value. The current Cash Flow from Financing is €-2.5 Mil. Akebia Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Cash Flow from Financing is €-2.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued.
The current stock price of €1.17 is trading 4.3% above its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for STU:AX9:
Cash Flow from Financing: €-2.5 Mil
GF Value™: €1.12 vs. price of €1.17 (4.3% above fair value)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score
Get the complete analysis for STU:AX9
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
